GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Equity-to-Asset

HLS Therapeutics (TSX:HLS) Equity-to-Asset : 0.47 (As of Dec. 2023)


View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. HLS Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$131.07 Mil. HLS Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was C$280.48 Mil. Therefore, HLS Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.47.

The historical rank and industry rank for HLS Therapeutics's Equity-to-Asset or its related term are showing as below:

TSX:HLS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47   Med: 0.56   Max: 0.98
Current: 0.47

During the past 13 years, the highest Equity to Asset Ratio of HLS Therapeutics was 0.98. The lowest was 0.47. And the median was 0.56.

TSX:HLS's Equity-to-Asset is ranked worse than
64.31% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs TSX:HLS: 0.47

HLS Therapeutics Equity-to-Asset Historical Data

The historical data trend for HLS Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Equity-to-Asset Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.56 0.58 0.52 0.47

HLS Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.51 0.49 0.47 0.47

Competitive Comparison of HLS Therapeutics's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Equity-to-Asset falls into.



HLS Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

HLS Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=131.07/280.475
=0.47

HLS Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=131.07/280.475
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLS Therapeutics  (TSX:HLS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


HLS Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics (TSX:HLS) Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (TSX:HLS) Headlines

No Headlines